Nousjka P. A. Vranken

Nousjka P. A. Vranken

Auto-generated profile, based on publicly available information

Nousjka P. A. Vranken

Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2021 in Quality of Life Research
Verified
Journal Article
Open access
PDF file
EKE. R. Kurniawati
E. R. Kurniawati
VRV. G. H. Rutjens
V. G. H. Rutjens
NVN. P. A. Vranken
N. P. A. Vranken
TDT. S. R. Delnoij
T. S. R. Delnoij
RLR. Lorusso
R. Lorusso
PWP. W. Weerwind
P. W. Weerwind
Background: Veno-venous extracorporeal membrane oxygenation (VV-ECMO) has been used successfully for the past decade in adult patients with acute respiratory distress syndrome (ARDS) refractory to conventional ventilatory support. However, knowledge of the health-related quality of life (HRQoL) in VV-ECMO patients is still limited. Thus, this study aimed to provide a comprehensive overview of the HRQoL following VV-ECMO support in ARDS patients. Methods: A systematic search was performed on PubMed and Web of Science databases from January 1st, 2009 to October 19th, 2020. Studies reporting on HRQoL following VV-ECMO for ARDS in adults were included. Two authors independently selected studies, extracted data, and assessed methodological quality. Results: Eight studies were eligible for inclusion, consisting of seven observational studies and one randomized controlled trial (total N = 441). All eight studies had a quantitative design and reported 265 VV-ECMO survivors to have a reduced HRQoL compared to a generally healthy population. Follow-up time varied between six months to three years. Additionally, only four studies (total N = 335) compared the HRQoL of VV-ECMO (N = 159) to conventionally treated survivors (N = 176), with one study showing a significantly better HRQoL in VV-ECMO survivors, while three studies were stating comparable HRQoL across groups. Notably, most survivors in these studies appeared to experience varying degrees of anxiety, depression, and post-traumatic stress disorder (PTSD). Conclusions: ARDS survivors supported by VV-ECMO have a decline in HRQoL and suffered from physical and psychological impairments. This HRQoL reduction is comparable or even better to the HRQoL in conventionally treated ARDS survivors.

5 April 2025 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
NVNousjka P. A. Vranken
Nousjka P. A. Vranken
XLXinyu Li
Xinyu Li
HBHeleen Bouman
Heleen Bouman
SMSanne G. J. Mourmans
Sanne G. J. Mourmans
AAAnouk Achten
Anouk Achten
Jerremy WeertsJerremy Weerts
Jerremy Weerts
Background: Most patients with heart failure with preserved ejection fraction (HFpEF) have a metabolic phenotype in which comorbidities including diabetes mellitus play an important role. Factors related to impaired glucose metabolism, such as kidney disease, may contribute to adverse clinical events. Albuminuria is an early marker of kidney disease. We assessed the prevalence of impaired glucose metabolism and albuminuria in HFpEF over time, and evaluated its prognostic implications. Methods: Consecutive patients referred to our outpatient clinic and diagnosed with HFpEF between March 2015–November 2023 were included in this study. Patients with type 1 diabetes were excluded. Patients were stratified according to baseline glucose metabolism status (DM + for prediabetes and diabetes, or DM−) and albuminuria status (ALB+ or ALB− for albuminuria > 3.0 mg/mmol and normoalbuminuria, respectively). The primary outcome was a composite of HF hospitalizations (HFH) and all-cause mortality, and was analysed using multivariable-adjusted Cox-regression models. Results: Among 332 patients with HFpEF (median age 77 years; 67% female), 121 (36.4%) were classified as DM−/ALB−, 106 (31.9%) as DM+ /ALB−, 44 (13.3%) as DM−/ALB+, and 61 (18.4%) as DM+ /ALB+. Both baseline DM and ALB were independently associated with the primary outcome after approximately 3 years: adjusted hazard ratio (aHR) 1.93; 95% confidence interval (CI) 1.25–2.97 and 1.58; 95%CI 1.04–2.41, respectively. Patients in the DM+ /ALB+ group showed the highest risk (aHR 2.85; 95%CI 1.57–5.15). After one year, DM/ALB status was re-evaluated in 250 (75%) patients. New DM+ and ALB+ incidence was 3.9% and 22%in those at risk, respectively. Patients particularly changed ALB groups compared to baseline (n = 63, 25.2%); 27 (10.8%) patients recovered from albuminuria. At 3 years follow-up, the primary outcome mainly occurred in patients who consistently showed albuminuria (27.1%) or who recovered from albuminuria (22.2%), and less so in patients who developed albuminuria after one year (13.9%) or who remained free of albuminuria (8.6%) (p = 0.008). Conclusions: DM and albuminuria are prevalent in HFpEF at baseline, and re-evaluation one year later still reveals new diagnoses. Both factors are independently associated with adverse outcomes. Albuminuria at any time point remains predictive of adverse outcomes in HFpEF. Graphical Research insights: What is currently known about this topic?: Diabetes mellitus is an important cardiovascular risk factor in patients with HFpEF, contributing to disease progression and worse outcomes. Albuminuria is a prognostic marker in heart failure patients and more prevalent in patients with diabetes What is the key research question?: What is prevalence of impaired glucose metabolism and albuminuria in HFpEF over time and how does this translate to prognosis? What is new?: Both DM and albuminuria each independently associated with worse prognosis in HFpEF. Screening 1 year after HFpEF diagnosis yielded incidence rates of 3.9% and 10.8% for DM and prediabetes, respectively, and 22% for albuminuria. Albuminuria at any time point appeared prognostic in HFpEF, also when albuminuria recovered How might this study influence clinical practice?: Intermittent screening of HFpEF patients for abnormal glucose metabolism and albuminuria is warranted to optimize risk management

15 March 2015 in The Journal of ExtraCorporeal Technology
Verified
Journal Article
Open access
PDF file
EŠErvin E. Ševerdija
Ervin E. Ševerdija
NVNousjka P.A. Vranken
Nousjka P.A. Vranken
STSteven Teerenstra
Steven Teerenstra
YGYuri M. Ganushchak
Yuri M. Ganushchak
PWPatrick W. Weerwind
Patrick W. Weerwind
Previous studies showed that decreased cerebral saturation during cardiac surgery is related to adverse postoperative outcome. Therefore, we investigated the influence of intraoperative events on cerebral tissue saturation in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). A total of 52 adult patients who underwent cardiac surgery using pulsatile CPB were included in this prospective explorative study. Cerebral tissue oxygen saturation (SctO2) was measured in both the left and right cerebral hemisphere. Intraoperative events, involving interventions performed by anesthesiologist, surgeon, and clinical perfusionist, were documented. Simultaneously, in-line hemodynamic parameters (partial oxygen pressure, partial carbon dioxide pressure, hematocrit, arterial blood pressure, and CPB flow rates) were recorded. Cerebral tissue saturation was affected by anesthetic induction (p < .001), placement of the sternal retractor (p < .001), and initiation (p < .001) as well as termination of CPB (p < .001). Placement (p < .001) and removal of the aortic cross-clamp (p = .026 for left hemisphere, p = .048 for right hemisphere) led to changes in cerebral tissue saturation. In addition, when placing the aortic cross-clamp, hematocrit (p < .001) as well as arterial (p = .007) and venous (p < .001) partial oxygen pressures changed. Cerebral tissue oximetry effectively identifies changes related to surgical events or vulnerable periods during cardiac surgery. Future studies are needed to identify methods of mitigating periods of reduced cerebral saturation.

3 February 2020 in Perfusion
Verified
Journal Article
Open access
PDF file
NVNousjka Pa Vranken
Nousjka Pa Vranken
ZBZaheer Ud Babar
Zaheer Ud Babar
JMJesse A Montoya
Jesse A Montoya
PWPatrick W Weerwind
Patrick W Weerwind
Background: Efforts have been made to minimize transfusion of packed red blood cells in patients undergoing cardiac surgery with cardiopulmonary bypass. One method concerns retrograde autologous priming. Although the technique has been used for decades, results remain contradictory in terms of transfusion requirements. Objective: This systematic literature review aimed to summarize the evidence for the efficacy of retrograde autologous priming in terms of decreasing perioperative packed red blood cell requirements in adults. Methods: Two researchers independently searched PubMed for articles published in the past 10 years. The modified Cochrane collaboration Risk of Bias Tool and the Research Triangle Institute Item Bank were used to assess bias. Results: Eight studies were included, of which two randomized and six observational studies. Five studies, including one randomized study, report a significant decrease in packed red blood cell use in the retrograde autologous priming group compared to no retrograde autologous priming used. All studies are flawed by at least a high risk bias of bias score on one item of the bias assessment. Conclusion: Although most studies reported significantly fewer packed red blood cell transfusions in the retrograde autologous priming group, it is important to note that relatively few articles are available which are flawed by several types of bias. Prospective, randomized multi-center trials are warranted to conclude decisively on the benefits of retrograde autologous priming.

12 January 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
TPTobias F.S. Pustjens
Tobias F.S. Pustjens
NVNousjka P.A. Vranken
Nousjka P.A. Vranken
RHRenicus S. Hermanides
Renicus S. Hermanides
SRSaman Rasoul
Saman Rasoul
JOJan P. Ottervanger
Jan P. Ottervanger
AHArnoud 't van 't Hof
Arnoud 't van 't Hof